December 08, 2022

Valeo Pharma keeps delivering with a 100% revenue growth forecast in 2022 and more new effective pharmaceuticals

Early in 2022 InvestorIntel updated readers about a company that was growing its revenue at an incredible rate of 128%. Fast forward to today and the same company continues to impress with a forecast FY 2022 revenue guidance “exceeding 100% compared to fiscal 2021.” That’s Tesla-like growth. Wow!

The company is Valeo Pharma Inc. (TSX: VPH | OTCQB: VPHIF) (“Valeo”).

So how is the company growing its revenue so fast you might ask?

Valeo’s specialty pharmaceuticals are selling very well, their business model allows Valeo to rapidly bring new pharmaceuticals to market, and their product range keeps growing

Valeo’s leading products in 2022 include asthma medicines Enerzair® and Atectura®, the low molecular weight heparin biosimilar REDESCA™, as well as the recently added ophthalmology products XIIDRA® SIMBRINZA®, and the ant-allergy product ALLERJECT®.

Valeo CEO Steve Saviuk stated: “Our lead products have delivered the strong growth we forecasted for 2022. With a first full year of commercial activities for Enerzair and Atectura now completed, both products are generating strong sequential quarterly increases in the number of total prescribers, total prescriptions and revenues…..The recent addition of our ophthalmic and severe allergy products in early August materially impacted our fourth quarter and we expect them to significantly contribute to our overall 2023 revenues as well”.

Valeo’s business model is also part of the reason for the rapid acceleration in revenues, as the company forms partnerships with pharmaceutical companies that do the research & development and manufacturing while Valeo concentrates on the regulatory requirements and the sales and marketing of the pharmaceutical products.

Valeo continues to grow its portfolio of products. In September 2022 Valeo announced a new product “sabizabulin”. Valeo entered into a Commercial Services Agreement with Veru Inc. for sabizabulin for the treatment of COVID-19 in Canada. Sabizabulin is a new dual antiviral and anti-inflammatory agent being targeted for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome and death. Anti-viral drugs are all the rage nowadays so this looks potentially like a winning move by Valeo. Valeo reported: “Treatment with sabizabulin 9 mg once daily, an oral, first-in-class, new chemical entity, microtubule disruptor that has dual anti-inflammatory and antiviral properties, resulted in a clinically meaningful and statistically significant 55.2% relative reduction in deaths compared to placebo. The results of the interim analysis of the Phase 3 COVID-19 study have been published in The New England Journal of Medicine (NEJM) Evidence.

Note: Bold emphasis by the author.

Valeo’s product range of pharmaceuticals crosses several areas of medicine

Source: Valeo Pharma website

There is a lot to like about Valeo Pharma. The Company has been delivering on its targets and the management continues to successfully grow the business.

Valeo Pharma trades on a market cap of C$51 million. One to watch out for in 2023.

Disclaimer: The author of this post may or may not be a shareholder of any of the companies mentioned in this column. None of the companies discussed in the above feature have paid for this content. The writer of this article/post/column/opinion is not an investment advisor, and is neither licensed to nor is making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence. To access the InvestorIntel.com disclaimer and other important legal notices, click here.

Leave a Reply

Your email address will not be published. Required fields are marked *